Clinical Trial Update: A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years [Phase 3]

View source ↗

Summary

Phase 3 study evaluating immunogenicity and safety of Group ACYW135 meningococcal conjugate vaccine (CRM197) in adults 18-55, sponsored by CanSino Biologics. St…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Meningitis

Drugs mentioned

• Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (Meningococcal conjugate vaccine (CRM197) for groups A, C, W-135, Y)

Snippet

Sponsor: CanSino Biologics Inc. | Conditions: Meningococcal Meningitis | Phase 3 | Status: ACTIVE_NOT_RECRUITING